The Price Is Right: Cell And Gene Therapy Approvals And Market Access In 2023

The cell and gene therapy regulatory and market access landscape is continually evolving, making it challenging for sponsors to balance new regulatory guidance and the expectations of payors. Starting health economic evidence development and market access planning as early as possible in clinical development for a cell and gene therapy is important for demonstrating the value to payers and health technology appraisal (HTA) organizations.

In this white paper, experts discuss product valuation strategies that effectively balance a treatment’s value and benefit with affordability, collecting evidence to support broad approval, and how innovative payment schemes could help increase access to advanced therapies.